WO2020209702A1 - Composition pour l'amélioration, le traitement ou la prévention d'affections cutanées comprenant du jus d'echinacea purpurea - Google Patents

Composition pour l'amélioration, le traitement ou la prévention d'affections cutanées comprenant du jus d'echinacea purpurea Download PDF

Info

Publication number
WO2020209702A1
WO2020209702A1 PCT/KR2020/004992 KR2020004992W WO2020209702A1 WO 2020209702 A1 WO2020209702 A1 WO 2020209702A1 KR 2020004992 W KR2020004992 W KR 2020004992W WO 2020209702 A1 WO2020209702 A1 WO 2020209702A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
allergic
inflammatory skin
skin diseases
juice
Prior art date
Application number
PCT/KR2020/004992
Other languages
English (en)
Korean (ko)
Inventor
박수진
김세민
유용환
호성현
Original Assignee
이연제약 주식회사
주식회사 지앤피바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200044163A external-priority patent/KR20200120550A/ko
Application filed by 이연제약 주식회사, 주식회사 지앤피바이오사이언스 filed Critical 이연제약 주식회사
Publication of WO2020209702A1 publication Critical patent/WO2020209702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a composition for improving, treating or preventing skin diseases, particularly allergic or inflammatory skin diseases, and more particularly, a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases comprising the juice of Jasper Cheonin Guk as an active ingredient , It relates to a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, a food composition for improving allergic or inflammatory skin diseases, or a feed composition for improving allergic or inflammatory skin diseases.
  • Human skin consists of the dermis and epidermis.
  • the epidermis located at the outermost part of the skin, protects against various stimuli from the outside, such as physicochemical stimuli such as chemicals, air pollutants, dry environments, and ultraviolet rays, and prevents excessive release of body moisture through the skin. It performs a protective function of preventing.
  • the outermost stratum corneum is formed from keratinocytes, and consists of keratinocytes that have been differentiated and the lipid layer surrounding them. Keratinocytes are eliminated from the skin after a certain period of time, and new keratinocytes raised from the lowermost layer of the epidermis take over their function.These repetitive processes of change are called epidermis differentiation or keratinization. .
  • keratinocytes form a stratum corneum while generating natural moisturizing factor (NMF) and intercellular lipids, making the stratum corneum firm and flexible, acting as a barrier to the outside as a skin barrier. You will have the function.
  • NMF natural moisturizing factor
  • the stratum corneum may easily lose its function due to excessive washing, lifestyle factors such as bathing, environmental factors such as dry air pollutants, and endogenous diseases such as atopic skin or senile skin.
  • lifestyle factors such as bathing
  • environmental factors such as dry air pollutants
  • endogenous diseases such as atopic skin or senile skin.
  • the rate of formation and dropout of the stratum corneum is slowed due to changes in dietary habits, and the amount of moisturizing factors and lipids in the stratum corneum decreases due to the decline in the function of keratinocytes.
  • moisturizing factors and lipids in the stratum corneum decreases due to the decline in the function of keratinocytes.
  • stratum corneum does not function as a normal skin barrier.
  • atopic dermatitis is an allergic or inflammatory skin disease that has a high risk as the prevalence of atopic dermatitis increases rapidly in recent years.It is estimated that it is related to genetic factors and immune system deficiency, but the exact cause has not yet been identified. It is expected to be somewhat alleviated through improvement of diet, but there is no fundamental treatment method.
  • atopic dermatitis causes IgE to be produced in mast cells in the process of removing allergens that have come into contact with or in the body, and if it comes into contact with or comes in with the same allergens, the human body becomes hypersensitive to allergens. As a result, histamine is produced, leading to atopic dermatitis.
  • steroid topical drugs As the treatment for atopic dermatitis, steroid topical drugs, antihistamines, calcineurin inhibitors, antibiotics, and ultraviolet therapy have been mainly used.However, in the case of long-term use, skin atrophy, capillary dilation, etc. A reaction has occurred and there is a limitation due to various side effects such as a risk of inducing adrenal suppression, so there are relatively few side effects and interest in new treatments capable of treating atopic dermatitis is increasing.
  • Echinacea purpurea is a perennial plant of the Asteraceae family, native to North America, and is widely cultivated for ornamental purposes all over the world because of its gorgeous flowers, and is also used as a remedy for colds and various viral infections by enhancing immunity.
  • the problem to be solved by the present invention is to provide a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jasper Cheonin Guk as an active ingredient.
  • Another problem to be solved by the present invention is to provide a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheonin Guk as an active ingredient.
  • Another problem to be solved by the present invention is to provide a food composition for improving allergic or inflammatory skin diseases, including the juice of Jajucheonin-guk as an active ingredient.
  • Another problem to be solved by the present invention is to provide a feed composition for improving allergic or inflammatory skin diseases, including the juice of Jagalcheoninguk as an active ingredient.
  • the present invention provides a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheonin Guk as an active ingredient in order to achieve the above object.
  • the allergic or inflammatory skin disease is skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, chronic lichen planus, intermittent dermatitis, deprived dermatitis, papular urticaria, psoriasis, psoriatic arthritis.
  • Sun dermatitis, sunburn and acne may be any one of the skin diseases selected from.
  • the self-made heaven-in-guk may be a stem, leaf, or above-ground outpost of the self-made heaven-in-guk.
  • the pharmaceutical composition may be an oral formulation.
  • the oral preparation may be a powder, granule, tablet, capsule, troche, suspension, emulsion, syrup or aerosol.
  • the present invention provides a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jasper Cheon In Guk as an active ingredient.
  • the present invention provides a food composition for improving allergic or inflammatory skin diseases, including the juice of Jajucheonin-guk as an active ingredient.
  • the food composition may be a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation, or beverage formulation.
  • the food composition may be a health functional food for improving allergic or inflammatory skin diseases.
  • the present invention provides a feed composition for improving allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
  • the present invention provides a method for treating allergic or inflammatory skin diseases in which the composition is orally administered to humans or animals other than humans.
  • the present invention provides a novel use of the juice for the treatment of allergic or inflammatory skin diseases, or for the manufacture of veterinary medicine.
  • composition for improving, treating, or preventing allergic or inflammatory skin diseases comprising the juice of Jasper Cheonin Guk as an active ingredient of the present invention reduces swelling of the ear in an animal model of inflammatory skin disease, and in blood tests, total leukocytes, neutrophils, eosinophils, As it reduces the level of IgE, pharmaceutical compositions for treating or preventing allergic or inflammatory skin diseases, pharmaceutical compositions for animals for treating or preventing allergic or inflammatory skin diseases, food compositions for improving allergic or inflammatory skin diseases, or allergic or It can be used as a feed composition for improving inflammatory skin diseases.
  • the inventors of the present invention evaluated the level of total leukocytes, neutrophils, eosinophils, blood IgE, etc. in ear edema and blood tests by orally administering Jagal Cheonin Guk juice in an allergic or inflammatory skin disease animal model. As a result, it was confirmed that the oral administration of Jajucheonin-guk juice has a remarkable therapeutic effect on allergic or inflammatory skin diseases.
  • the present invention relates to a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising a juice juice of Jagalcheoninguk as an active ingredient.
  • the present invention relates to a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
  • juice liquor' as used in the present invention refers to a juice obtained by compressing, pulverizing and compressing the stem, leaves, or above-ground outposts, fractions fractionated from them, concentrates obtained by additionally concentrating these juices or fractions, Purified or separated purified product is also included, and the juice, fraction, concentrate, or purified product is dried or dried or pulverized.
  • Jasper Cheonin Guk juice powder In order to prepare 1 part by weight of the Jasper Cheonin Guk juice powder, about 20 to 100 parts by weight, preferably 30 to 60 parts by weight of undried Jasper Cheoninguk juice, and 1 part by weight of the Jasper Cheon In Guk juice powder 10 to 50 parts by weight of the liquid, preferably 15 to 30 parts by weight, are required.
  • the Jagal Cheonin Guk juice is remarkably effective in treating allergic or inflammatory skin diseases compared to the aqueous extract of Jagal Cheonin Guk using water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, or a fat-soluble extract fractionated with hexane, ethyl acetate, etc. outstanding.
  • the juice of the Jasper Cheonin Guk may be a juice of leaves, stems of Echinacea purpurea , or the above-ground outposts including the same, but the efficacy of reducing allergic or inflammatory skin diseases by oral administration is excellent.
  • the term'allergic or inflammatory skin disease' used in the present invention may include, without limitation, skin diseases that moisturize an allergic or inflammatory reaction occurring in the skin, for example, skin inflammation, eczema, contact dermatitis, atopic dermatitis. , Seborrheic dermatitis, chronic lichen planus, interstitial, deprived dermatitis, papular urticaria, psoriasis, psoriatic arthritis, sun dermatitis, sunburn and acne, preferably any one skin disease, preferably chronic refractory allergic or It may be atopic dermatitis, an inflammatory skin disease.
  • The'pharmaceutical composition','pharmaceutical','veterinary pharmaceutical composition', or'veterinary medicine' is an active ingredient, in addition to the juice of Jasper Cheonin Guk, a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions, etc. Can include.
  • The'carrier' is a compound that facilitates the addition of the compound into cells or tissues.
  • The'excipient' is a compound added to provide an appropriate form to the active ingredient to be formulated or to increase the amount for convenient use.
  • The'diluent' is a compound that is diluted in water to dissolve the compound as well as stabilize the biologically active form of the target compound.
  • the carrier, excipient, and diluent do not need to be particularly limited, but for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the amount of use of the pharmaceutical composition, medicament, veterinary pharmaceutical composition or veterinary medicament may vary depending on the age, sex, and weight of the patient or the animal to be treated, and above all, the condition of the subject to be treated, a specific category of the disease to be treated, or It will depend on the type, route of administration and the nature of the therapeutic agent used.
  • the pharmaceutical composition, medicament, veterinary pharmaceutical composition or veterinary medicament is appropriately selected according to the absorption of the active ingredient in the body, the excretion rate, the age and weight, sex and condition of the patient or the animal to be treated, and the severity of the disease to be treated. , In general, it is preferred to administer 10 to 5,000 mg per day, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, and most preferably 200 to 2,000 mg per day.
  • the unit dosage form formulation thus formulated may be administered several times at regular time intervals as needed.
  • the pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament may be individually administered as a prophylactic or therapeutic agent, or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent.
  • the pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament is formulated and used in oral preparations such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc., according to a conventional method.
  • oral preparations such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc.
  • I can.
  • formulation it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and such solid preparations include at least one excipient for the compound, such as starch, calcium carbonate, sugar or lactose, gelatin. It can be prepared by mixing and the like. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. .
  • the treatment method of the allergic or inflammatory skin disease is to orally administer the composition to humans or non-human animals, especially mammals, for example, oral administration of the composition to an individual to be treated with an allergic or inflammatory skin disease. It is to administer.
  • the dosage, administration method, and number of administrations for the treatment may refer to the dosage, administration method, and number of administrations of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or animal medicine.
  • the present invention relates to a food composition for improving allergic or inflammatory skin diseases, comprising the juice of Jajucheoninguk as an active ingredient.
  • The'food composition' includes food ingredients and food additives described in the Code of Food Additives, which can be used as foods described in the standards and standards of foods commonly used in food manufacturing ('Food Code'), in addition to the juice juice of Jasper Cheonin Guk as an active ingredient. Can include.
  • the food composition is not particularly limited, but may include, for example, carbohydrates and flavoring agents.
  • the carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sugar, lactose, and the like; Oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin, and the like; Sugar alcohols such as xylitol, sorbitol, erythritol, and the like can be used.
  • the flavoring agent may be a natural flavoring agent [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)] and a synthetic flavoring agent (saccharin, aspartame, etc.).
  • the juice of Jagaloninguk does not need to be particularly limited as long as it has an effect of improving allergic or inflammatory skin diseases, but, for example, 0.1 to 99% by weight, 0.5 to It may be included in 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, 5 to 50% by weight.
  • the juice juice of Jajucheonin-guk which is an active ingredient, varies depending on the condition, weight, and the presence or absence of disease and the duration of the ingestion, but may be appropriately selected by a skilled person.
  • it may be 10 to 5,000 mg, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, most preferably 200 to 2,000 mg per day, based on the daily dosage, and the number of administration is particularly
  • it does not need to be limited, it can be adjusted by a person skilled in the art within the range of 3 times a day to once a week.
  • long-term intake for the purpose of health and hygiene or for the purpose of health control it may be less than the above range.
  • the food composition is not particularly limited, but may be, for example, a powder, a granule, a tablet, a capsule, a pill, an extract, a jelly formulation, a tea bag formulation, or a beverage formulation.
  • the juice of Jagalcheoninguk may be added.
  • Foods that can be added do not need to be particularly limited, but for example, confectionery, bread or rice cakes, processed cocoa products or chocolates, meat, etc. as exemplified in the food standards and standards ('Food Code') according to Article 7 of the Food Sanitation Act.
  • it may be added to dairy products, processed meat products and packaged meats, and egg products exemplified in the processing standards and ingredient specifications of livestock products according to Article 4 of the Livestock Hygiene Management Act ('Livestock Products Code').
  • the food composition containing the juice of Jaju Cheonin Guk as an active ingredient is a health functional food for improving allergic or inflammatory skin diseases, for example, a health functional food for improving atopic dermatitis, "health functional food that helps alleviate hyperimmune reactions" Or, it may be used as "health functional food that helps improve skin condition due to immune hypersensitivity reaction”.
  • The'health functional food' refers to a food manufactured (including processing) in accordance with legal standards using raw materials or ingredients having useful functions for the human body (Article 3, No. 1 of the Health Functional Food Act).
  • The'health functional food' may differ in terms or ranges from country to country, but'Dietary Supplement' in the United States,'Food Supplemnet' in Europe,'Health Functional Food' in Japan or ' It may correspond to'Food for Special Health Use (FoSHU)' and'Health Food' in China.
  • the food composition or health functional food may additionally contain food additives, and the suitability as a food additive shall be determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the'Food Additive Code' unless otherwise specified.
  • the above health functional foods are'functional raw materials' used in "health functional foods that help alleviate hyperimmune reactions" or "health functional foods that help improve skin conditions due to immune hypersensitivity reactions” together with Jagal Cheonin Guk juice.
  • the present invention relates to a feed composition for improving allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
  • The'feed composition' can be used as an active ingredient, as well as food ingredients and food additives listed in the Food Additives Code, which can be used as foods specified in the standards and standards of food ('Food Code'), in addition to the juice of Jasper Cheonin Guk. Even if it is not a possible food raw material or food additive, raw materials that fall within the range of sweet feeds in Appendix 1 of'Standards and Specifications for Feed, etc.' and raw materials that fall within the range of auxiliary feeds in Appendix 2 can be used.
  • The'feed composition' may be an extractant among auxiliary feeds according to'standards and standards for feed, etc.', and may be a blended feed including the auxiliary feed.
  • the juice of Jagalcheoninguk does not need to be particularly limited as long as it has an effect of improving allergic or inflammatory skin diseases, but, for example, 0.1 to 99% by weight, 0.5 to It may be included in 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, 5 to 50% by weight.
  • the juice of Jagalcheonin-guk which is an active ingredient, varies depending on the condition, weight, and the presence or absence of disease and the duration of the ingested animal, but may be appropriately selected by a person skilled in the art.
  • the number of administration is not particularly limited, but can be adjusted by a skilled person within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be less than the above range.
  • DEX 'Dexamethasone Tablet
  • NC/Nga mice show a pattern of atopic dermatitis accompanied by overproduction of IgE, clinically and histologically, very similar to the lesions of human atopic dermatitis, and there are many cases that have been used as atopic dermatitis animal models. I chose.
  • auricle and the back of the neck of NC/Nga mice were depilated with a razor, and then, an appropriate amount of a depilatory agent was applied to remove the hair.
  • atopic dermatitis-inducing reagent Biostir AD, Biostir Inc., Japan
  • Biostir AD Biostir AD, Biostir Inc., Japan
  • the skin clinical index was evaluated and distributed in a random method so that the average level of each group was distributed as uniformly as possible according to the ranked levels of atopic dermatitis.
  • atopic dermatitis-inducing reagent was applied to the auricle, neck, and forelimb locations a total of 10 times on days 15, 19, 22, 26, 29, 33, 36, 40, 43 and 47. It was evenly applied to the back of the body.
  • Group 1 of them induces atopic dermatitis for 2 weeks in the normal control group, and the remaining 4 groups induce atopic dermatitis for 2 weeks.
  • Group 3 is 200 mg/kg based on the solid content of the juice extract excluding excipients
  • Groups 1-4 are 200 mg/kg based on the solid content of the extract of'Styria extract'
  • Groups 1-5 are the active ingredient of'Dexamethasone' 2 mg/kg was administered orally once a day based on a 10 mL/kg dose.
  • the normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.
  • the body weights of all test substance-administered groups 1-3 to 1-5 were significantly lower than that of the normal control group 1-1 (p ⁇ 0.05). , p ⁇ 0.05 and p ⁇ 0.001), in particular, the body weight of group 1-5 to which dexamethasone was administered was significantly lower than that of group 1-2, which is the negative control group (p ⁇ 0.01).
  • the ear thickness of the group 1-3 administered with the extract of Jajucheonin-guk showed a tendency to decrease somewhat compared to the negative control group of Group 1-4, and showed a similar tendency to that of the group 1-4 administered with the extract.
  • the negative control group of group 1-2 and the group 1-4 treated with stalk extract were significantly higher than that of the positive control group of group 1-1 (p ⁇ 0.001 and p ⁇ 0.05).
  • group 3 the group administered with the juice solution of Jagalcheonin-guk and the group administered with dexamethasone in groups 1-5 were significantly lower than those in the negative control group in group 1-2 (p ⁇ 0.01 and p ⁇ 0.05).
  • the negative control group 1-2 and the group 1-4 administration group were significantly higher than the positive control group 1-1 (p ⁇ 0.001 and p ⁇ 0.01).
  • the group 3 administered with the juice of Jinghui Cheonin Guk and the group 1-5 administered with dexamethasone were significantly lower than those of the negative control group 1-2 (p ⁇ 0.001 and p ⁇ 0.001).
  • the group 1-3 administered with the extract of Jajucheonin-guk significantly reduced both neutrophils and eosinophils, which play an important role in the pathologic mechanism of atopic dermatitis, and was particularly superior to the group 1-4 treated with styrofoam extract. And, it was confirmed to be at a similar level to the dexamethasone-administered group of groups 1-5 of the positive control group 2.
  • EPE water extract
  • EPE water extract
  • the extract obtained by extracting the dried product of Echinacea purpurea outpost with water at 100°C was used.
  • the solid content of the water extract (EPE) was 4.9% by weight.
  • DEX dexamethasone tablet
  • 'Protopic ointment 0.1% (tacrolimus hydrate)' was purchased and used as a positive control for transdermal administration (positive control 3).
  • 0.1% of the protopic ointment is a white to pale yellow ointment containing 1.02 mg/g of tacrolimus hydrate.
  • mice, breeding conditions, and methods of inducing atopic dermatitis were all performed in the same manner as in Experimental Example 1.
  • atopic dermatitis-inducing reagent was applied to the back of the auricle, neck and forelimbs for a total of 8 times until day 15, 19, 22, 26, 29, 33, 36 and 40. It was applied uniformly, and an autopsy was performed on the 42nd day.
  • group 1 of them induces atopic dermatitis for 2 weeks in the normal control group, and the other 6 groups induce atopic dermatitis for 2 weeks.
  • Group 3 is administered 200 mg/kg orally based on the solid content of the juice extract excluding excipients
  • Group 2-4 is administered orally 200 mg/kg based on the solid content of the extract
  • Group 2-5 is the active ingredient of'dexamethasone'. 2 mg/kg was administered orally once a day based on a 10 mL/kg dose.
  • the normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.
  • groups 2-6 were transdermally administered 200 mg/kg to the atopy-induced back area at 10 mL/kg/day based on the solid content of the juice extract excluding excipients, and group 2-7 was administered 0.1% Protopic Ointment. It was administered transdermally at 100 mg/mari/day.
  • the percentage of leukocytes was confirmed using the blood collected on the day 42 of necropsy on the 42nd day of induction of atopic dermatitis.
  • the ratio of lymphocytes, eosinophils and basophils using an automatic blood analyzer (ADVIA 2120, SIEMENS, USA) after injecting some of the collected blood into a CBC bottle containing an anticoagulant EDTA-2K It is shown in Table 7 to confirm.
  • atopic dermatitis the number of inflammation-related cells, in particular, the ratio of eosinophils is increased, and eosinophils are known to play an important role in the pathological mechanisms of atopic dermatitis.
  • the proportion of eosinophils was significantly increased in the oral administration group of the negative control group 2-2 compared to the oral administration group of the normal control group 2-1 (p ⁇ 0.01), and in groups 2-3 to 2 It was significantly decreased in group 7 compared to the negative control group of group 2-2 (p ⁇ 0.01, p ⁇ 0.001),
  • the oral administration group of Epjeong-in-guk juice (EPJ) of group 2-3 was the oral administration group of EPE-dosed water extract (EPE) of group 2-4, and the transdermal administration of EPJ of group 2-7
  • EPE EPE-dosed water extract
  • the proportion of basophils did not show any significant difference between the groups, but the oral administration group of JJV (EPJ) in group 2-3, positive control group 2 in group 2-5, and positive control group 3 in group 2-7. Showed a relatively low ratio compared to other groups.
  • EPJ oral administration group of JJV
  • the ratio of lymphocytes and eosinophils was significantly reduced when administered orally, and when administered orally, the ratio of lymphocytes and eosinophils was significantly reduced when administered orally. It was confirmed that it was more effective in ordering.
  • Experimental Example 1 and Experimental Example 2 are expressed as mean ⁇ standard deviation, and in the case of parametric multiple comparison, the normality of the data was assumed, and the result was tested by a parametric one-way variance analysis (One-way ANOVA). If is significant, a post-test was performed using Dunnett's multiple comparison test to analyze significant differences between test groups. In the case of nonparametric multiple comparisons, the test was performed with the Kruskal-Wallis'H-test, and if the result was significant, the significant difference between the test groups was analyzed using the post-analysis Mann-Whitney U test.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional tablet preparation method.
  • the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
  • Vitamin A acetate 70 ⁇ g
  • Vitamin B12 0.2 ⁇ g
  • composition ratio of the vitamin and mineral mixture ingredients suitable for health functional foods are mixed in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a general health functional food manufacturing method.
  • granules are prepared and can be used to prepare a health functional food composition according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare a functional beverage composition.

Abstract

La présente invention concerne une composition pour l'amélioration, le traitement ou la prévention d'affections cutanées allergiques ou inflammatoires. Plus précisément, la composition comprend du jus d'Echinacea purpurea en tant que principe actif, elle soulage l'œdème des oreilles chez un modèle animal d'affection cutanée inflammatoire et réduit les taux de globules blancs entiers, de neutrophiles, d'éosinophiles, d'IgE sanguines et analogues dans un test sanguin, et en conséquence, peut être utilisée comme composition pharmaceutique pour le traitement ou la prévention d'affections cutanées allergiques ou inflammatoires, composition pharmaceutique destinée à être utilisée chez des animaux pour le traitement ou la prévention d'affections cutanées allergiques ou inflammatoires, composition alimentaire pour l'amélioration d'affections cutanées allergiques ou inflammatoires, ou composition alimentaire pour animaux pour l'amélioration d'affections cutanées allergiques ou inflammatoires.
PCT/KR2020/004992 2019-04-12 2020-04-13 Composition pour l'amélioration, le traitement ou la prévention d'affections cutanées comprenant du jus d'echinacea purpurea WO2020209702A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0042865 2019-04-12
KR20190042865 2019-04-12
KR1020200044163A KR20200120550A (ko) 2019-04-12 2020-04-10 자주천인국 착즙액을 포함하는 피부질환 개선, 치료 또는 예방용 조성물
KR10-2020-0044163 2020-04-10

Publications (1)

Publication Number Publication Date
WO2020209702A1 true WO2020209702A1 (fr) 2020-10-15

Family

ID=72752098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/004992 WO2020209702A1 (fr) 2019-04-12 2020-04-13 Composition pour l'amélioration, le traitement ou la prévention d'affections cutanées comprenant du jus d'echinacea purpurea

Country Status (1)

Country Link
WO (1) WO2020209702A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000014354A (ja) * 1998-06-30 2000-01-18 Maruho Co Ltd 抗アレルギーまたは抗炎症作用を有する組成物
JP2001098263A (ja) * 1999-09-30 2001-04-10 Fancl Corp 新規抗酸化組成物及び抗炎症組成物
JP2011529055A (ja) * 2008-07-22 2011-12-01 イズン ファーマシューティカルズ， インコーポレイテッド 局所的抗炎症配合剤
KR20180005261A (ko) * 2015-05-28 2018-01-15 시므라이즈 아게 자색 콘플라워 착즙을 포함하는 화장료 조성물
KR20180054628A (ko) * 2015-08-31 2018-05-24 독토르. 아우구스트 볼프 게엠베하 운트 코. 카게 아르쯔네이미텔 에키네시아 추출물과 리놀레산 유도체를 함유하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000014354A (ja) * 1998-06-30 2000-01-18 Maruho Co Ltd 抗アレルギーまたは抗炎症作用を有する組成物
JP2001098263A (ja) * 1999-09-30 2001-04-10 Fancl Corp 新規抗酸化組成物及び抗炎症組成物
JP2011529055A (ja) * 2008-07-22 2011-12-01 イズン ファーマシューティカルズ， インコーポレイテッド 局所的抗炎症配合剤
KR20180005261A (ko) * 2015-05-28 2018-01-15 시므라이즈 아게 자색 콘플라워 착즙을 포함하는 화장료 조성물
KR20180054628A (ko) * 2015-08-31 2018-05-24 독토르. 아우구스트 볼프 게엠베하 운트 코. 카게 아르쯔네이미텔 에키네시아 추출물과 리놀레산 유도체를 함유하는 조성물

Similar Documents

Publication Publication Date Title
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2014171781A1 (fr) Composition prévenant ou traitant les symptômes de la xylostomiase
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
WO2010107170A1 (fr) Composition pour traiter des maladies métaboliques
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
WO2013141581A1 (fr) Composition pharmaceutique ou aliment naturel comprenant des extraits de fruit de lonicera coerulea var. edulis en tant que principes actifs dans la prévention ou l'amélioration de maladies vasculaires cérébrales ischémiques
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
WO2018080156A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait de potentilla fragarioides en tant que principe actif
WO2023106777A1 (fr) Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci
WO2020209702A1 (fr) Composition pour l'amélioration, le traitement ou la prévention d'affections cutanées comprenant du jus d'echinacea purpurea
WO2019231211A1 (fr) Composition permettant la prévention ou le traitement de maladies allergiques, contenant comme principes actifs des extraits mélangés de deux végétaux ou plus sélectionnés parmi la racine d'asiasarum, la racine de platycodon, et cinnamomi ramulus
KR20200120550A (ko) 자주천인국 착즙액을 포함하는 피부질환 개선, 치료 또는 예방용 조성물
WO2019212300A1 (fr) Composition comprenant un extrait d'aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2020209701A1 (fr) Composition pour soulager, traiter ou prévenir des affections cutanées, contenant un extrait de thymus vulgaris
KR102450143B1 (ko) 타임 추출물을 포함하는 피부질환 개선, 치료 또는 예방용 조성물
WO2020204242A1 (fr) Composition antimicrobienne pour l'inhibition de bactéries buccales et film à désintégration orale
WO2020004989A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la cachexie comprenant du kimchi
WO2021261870A1 (fr) Composition comprenant de la 6'-hydroxy justicidine-b pour prévenir, améliorer ou traiter des maladies allergiques
WO2022250356A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies allergiques contenant de l'extrait de rose en tant que principe actif
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
US11547735B2 (en) Composition for ameliorating psoriasis symptoms containing extract of Thalictrum squarrosum steph

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20786929

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20786929

Country of ref document: EP

Kind code of ref document: A1